BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cho Y, Kim MS, Nam CM, Kang ES. Statin Use is Associated with Decreased Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. Sci Rep 2019;9:1467. [PMID: 30728421 DOI: 10.1038/s41598-018-38110-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Buechler C, Aslanidis C. Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma.Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865:158658. [PMID: 32058031 DOI: 10.1016/j.bbalip.2020.158658] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
2 Francis P, Forman LM. Statins Show Promise Against Progression of Liver Disease. Clin Liver Dis (Hoboken) 2021;18:280-7. [PMID: 34976372 DOI: 10.1002/cld.1143] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Li X, Liu L, Hu Y. Statin use and the prognosis of patients with hepatocellular carcinoma: a meta-analysis. Biosci Rep 2020;40:BSR20200232. [PMID: 32162652 DOI: 10.1042/BSR20200232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Satriano L, Lewinska M, Rodrigues PM, Banales JM, Andersen JB. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol 2019;16:748-66. [PMID: 31666728 DOI: 10.1038/s41575-019-0217-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
5 Ho YJ, Koh AS, Ong ZH, Ng CH, Kong G, Chew NW, Lim HN, Siddiqui MS, Muthiah MD. The Underutilization, Adverse Reactions and Efficacy of Statins after Liver Transplant: A Meta-Analysis and Systematic Review. Transplantology 2021;2:264-73. [DOI: 10.3390/transplantology2030025] [Reference Citation Analysis]
6 Tenen DG, Chai L, Tan JL. Metabolic alterations and vulnerabilities in hepatocellular carcinoma. Gastroenterol Rep (Oxf) 2021;9:1-13. [PMID: 33747521 DOI: 10.1093/gastro/goaa066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Ershov P, Kaluzhskiy L, Mezentsev Y, Yablokov E, Gnedenko O, Ivanov A. Enzymes in the Cholesterol Synthesis Pathway: Interactomics in the Cancer Context. Biomedicines 2021;9:895. [PMID: 34440098 DOI: 10.3390/biomedicines9080895] [Reference Citation Analysis]
8 Khajeh E, Moghadam AD, Eslami P, Ali-hasan-al-saegh S, Ramouz A, Shafiei S, Ghamarnejad O, Dezfouli SA, Rupp C, Springfeld C, Carvalho C, Probst P, Mousavizadeh SM, Mehrabi A. Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09192-1] [Reference Citation Analysis]
9 Jouve JL, Lecomte T, Bouché O, Barbier E, Khemissa Akouz F, Riachi G, Nguyen Khac E, Ollivier-Hourmand I, Debette-Gratien M, Faroux R, Villing AL, Vergniol J, Ramee JF, Bronowicki JP, Seitz JF, Legoux JL, Denis J, Manfredi S, Phelip JM; PRODIGE-11 investigators/collaborators. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. J Hepatol 2019;71:516-22. [PMID: 31125576 DOI: 10.1016/j.jhep.2019.04.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]